



Novel treatment options for precision oncology

Immune evasion is a hallmark of cancer, contributing significantly to the progression of malignancies and associated mortalities. An interdisciplinary approach led by acib can assess personalized treatment options for patients, as well as lay the foundation to designing novel treatments.

BACKGROUND

Cancer therapies have made tremendous progress during the last years, but there are still problems in tackling cancer types which are able to suppress T cell activation using an immune checkpoint blockade (ICB). Although targeting ICB therapeutically sounds promising, the response rate across several cancer types is only at about 20%. For the most common lymphoid malignancy i.e. diffuse large B cell lymphoma (DLBCL) it's even worse. The estimation of DLBCL incidences vary a lot between different countries ranging from 7 per 100,000 inhabitants in the USA to 135 per 100,000 inhabitants in Slovenia. Worldwide this would affect between 500,000 to 10,000,000 people with incidents rising. DLBCL can affect any age group including children. 25% of people suffering from DLBCL are classified as immune-depleted and have the poorest clinical outcome. There is a clear demand to develop combinational therapies to improve patient survival and to evaluate the responsiveness of DLBCL-patients prior to treatment application.

TECHNOLOGY

acib is leading a multi-disciplinary approach combining wet-lab human DLBCL patient-derived co-culture experiments with next generation sequencing and sophisticated bioinformatic analyses. The aim is to i) test for the best combinational therapy options *ex vivo* and ii) to discover transcriptional and immunological signatures characterizing patients as candidates for targeted therapies. This approach towards precision oncology will allow a personalized selection of treatment options for each patient and offer important considerations for the design of novel treatments.

acib has ample expertise in providing R&D services to various companies – check also our other project offers: <https://acib.at/offers/>

OFFER

acib offers to develop tools for efficient combinational therapies targeting DLBCL and to discover new cancer signatures for novel therapeutics. IP developed in such projects will be fully transferred to you as our investor/industrial partner.

acib-EXPERTS:

Dr. Julia Feichtinger
Dr. Alexander Deutsch

AVAILABLE FOR:

- Investments
- Joint Research Projects
- Contract Research

DEVELOPMENT STATUS:

Technology Readiness Level 2
(Technology concept formulated)

IPR:

Will be generated for you as our industrial partner / investor

KEYWORDS:

Bioinformatics
Cancer
Prediction tools
Combinational therapy
Personalized medicine
Immune Checkpoint Blockade (ICB)
Diffuse Large B Cell Lymphoma (DLBCL)

CONTACT

acib GmbH
Krenngasse 37
8010 Graz
tel: +43 316 873 9316
e-mail: bd@acib.at
www.acib.at